Urine Testing Method Developed for Ureterolithiasis
|
By LabMedica International staff writers Posted on 03 Jun 2020 |

Image: FlexStation 3 Microplate Reader measures absorbance, fluorescence intensity, fluorescence polarization, luminescence, and time-resolved fluorescence (Photo courtesy of Molecular Devices).
Ureterolithiasis (nephrolithiasis or kidney stones) is a disease affecting the urinary tract. Kidney stones occur due to buildup of certain salts and minerals that form crystals, which in turn stick together and enlarge to form a hard mass in the kidneys. The stones move into the urinary tract and can cause blood in the urine, considerable pain and blockages in the urinary system.
Metabolic testing of a kidney stone patient’s urine to identify metabolites such as minerals and solutes that cause stones to form is key for preventing future ones. This testing is currently done by requiring the patient to collect their urine over a 24-hour period in a large container. The container is then sent to a laboratory for analysis and the results normally come back in 7 to 10 days.
Scientists from the Pennsylvania State University (University Park, PA, USA) and their colleagues developed SLIPS-LAB (Slippery Liquid-Infused Porous Surface Laboratory), a droplet-based bioanalysis system, for rapid measurement of urinary stone–associated analytes. The ultra-repellent and antifouling properties of SLIPS, which is a biologically inspired surface technology, allow autonomous liquid handling and manipulation of physiological samples without complicated sample preparation procedures and supporting equipment.
The team used enzymatic and colorimetric assay kits to measure metabolic profiles in urine. The uric acid assay was obtained from BioAssay Systems (Hayward CA, USA). Calibration experiments were performed using SLIPS-LAB and a FlexStation 3 microplate reader (Molecular Devices, San Jose, CA, USA). The performance of SLIPS-LAB for a spot urine test was compared with manual procedures in 96-well plates. A validation study was performed using SLIPS-LAB for detecting urine samples from patients with urinary stones.
The six-plex SLIPS-LAB device was designed for metabolic evaluation of urinary stone disease. The device conducts colorimetric and enzymatic assays in parallel for detecting calcium, citrate, uric acid, oxalate, and pH, which are among the most clinically relevant urinary analytes to assess stone risk and treatment response. The urinary stone–associated analytes of 24-hour urine samples from 15 individuals were examined using SLIPS-LAB. To study the metabolic profiles, the data were normalized to typical physiological values of 24-hour urine.
The test results can then be read using a scanner or a cell phone, and the scanned image can then be analyzed using a computer algorithm. All these steps, according to the authors, would take approximately 30 minutes in a physician’s office. An added benefit, they said, is that SLIPS-LAB is more cost-effective than regular, 24-hour testing.
Pak Kin Wong, PhD, professor of biomedical engineering and the principal investigator of the study, said, “We demonstrated that SLIPS-LAB enables the reagent and sample to move themselves and perform the reactions for us. It means the technology doesn’t require a technician to run any test machinery, so it is possible to do the test in non-traditional settings, like a physician’s office or even the patient’s home.”
The authors concluded that SLIPS-LAB will allow detection in a timely and cost-efficient manner and provide actionable diagnostic information and personalized treatment suggestions to individuals with urinary stone disease. The study was published on May 22, 2020 in the journal Science Advances.
Metabolic testing of a kidney stone patient’s urine to identify metabolites such as minerals and solutes that cause stones to form is key for preventing future ones. This testing is currently done by requiring the patient to collect their urine over a 24-hour period in a large container. The container is then sent to a laboratory for analysis and the results normally come back in 7 to 10 days.
Scientists from the Pennsylvania State University (University Park, PA, USA) and their colleagues developed SLIPS-LAB (Slippery Liquid-Infused Porous Surface Laboratory), a droplet-based bioanalysis system, for rapid measurement of urinary stone–associated analytes. The ultra-repellent and antifouling properties of SLIPS, which is a biologically inspired surface technology, allow autonomous liquid handling and manipulation of physiological samples without complicated sample preparation procedures and supporting equipment.
The team used enzymatic and colorimetric assay kits to measure metabolic profiles in urine. The uric acid assay was obtained from BioAssay Systems (Hayward CA, USA). Calibration experiments were performed using SLIPS-LAB and a FlexStation 3 microplate reader (Molecular Devices, San Jose, CA, USA). The performance of SLIPS-LAB for a spot urine test was compared with manual procedures in 96-well plates. A validation study was performed using SLIPS-LAB for detecting urine samples from patients with urinary stones.
The six-plex SLIPS-LAB device was designed for metabolic evaluation of urinary stone disease. The device conducts colorimetric and enzymatic assays in parallel for detecting calcium, citrate, uric acid, oxalate, and pH, which are among the most clinically relevant urinary analytes to assess stone risk and treatment response. The urinary stone–associated analytes of 24-hour urine samples from 15 individuals were examined using SLIPS-LAB. To study the metabolic profiles, the data were normalized to typical physiological values of 24-hour urine.
The test results can then be read using a scanner or a cell phone, and the scanned image can then be analyzed using a computer algorithm. All these steps, according to the authors, would take approximately 30 minutes in a physician’s office. An added benefit, they said, is that SLIPS-LAB is more cost-effective than regular, 24-hour testing.
Pak Kin Wong, PhD, professor of biomedical engineering and the principal investigator of the study, said, “We demonstrated that SLIPS-LAB enables the reagent and sample to move themselves and perform the reactions for us. It means the technology doesn’t require a technician to run any test machinery, so it is possible to do the test in non-traditional settings, like a physician’s office or even the patient’s home.”
The authors concluded that SLIPS-LAB will allow detection in a timely and cost-efficient manner and provide actionable diagnostic information and personalized treatment suggestions to individuals with urinary stone disease. The study was published on May 22, 2020 in the journal Science Advances.
Latest Technology News
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
- AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
- AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
- AI Model Achieves Breakthrough Accuracy in Ovarian Cancer Detection
- Portable Biosensor Diagnoses Psychiatric Disorders Using Saliva Samples
- Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement

- Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
- Viral Biosensor Test Simultaneously Detects Hepatitis and HIV
- Acoustofluidic Device to Transform Point-Of-Care sEV-Based Diagnostics
- AI Algorithm Assesses Progressive Decline in Kidney Function
Channels
Molecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read moreAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more







 assay.jpg)
